Nastaran Karimi on Muck Rack

Nastaran Karimi

As seen in: MDPI, Cell Press, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nastaran

Contact Nastaran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions

|
By Fuduan Peng, Ansam Sinjab, Yibo Dai, Warapen Treekitkarnmongkol, Sujuan Yang, Tieling Zhou, Minyue Chen, Alejandra Serrano, Avantika B Krishna, Nastaran Karimi, Manvi Sharma, Akshay V Basi, Guangsheng Pei, Jianlong Liao, Yunhe Liu, Jiping Feng, Zahraa Rahal, Yang Liu, Jiahui Jiang, Kai Yu, Yuejiang Liu, Kyung Serk Cho, Jichao Chen, Luisa M. Solis, Sarah A. Mazzilli, Steven M. Dubinett, Tina Cascone, Avrum Spira, Stephen Swisher, Naoe Jimbo, Takuo Hayashi, Satsuki Kishikawa, Kazuya Takamochi, Tomoo Itoh, Takashi Yao, Kenji Suzuki, Neda Kalhor, Ignacio I. Wistuba, Mingyao Li, Seyed Javad Moghaddam, Junya Fujimoto, Jared K. Burks, Jeffrey Myers, Kadir C. Akdemir, Linghua Wang, Humam Kadara
| Cell Press
Keywords lung adenocarcinoma lung precursor lesions spatial transcriptomics Xenium in situ alveolar progenitors reactive type II pneumocytes proinflammatory pathways IL-1β epithelial-immune niche LUAD interception Introduction Lung adenocarcinoma (LUAD) is increasingly being diagnosed in smokers and never-smokers and has become the dominant histological subtype of lung cancer.1 Despite clinical advances, mortality of patients with advanced LUAD remains relatively high.2 Improving outcomes for...
Open in Who Shared Issue with article?

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions

|
By Nastaran Karimi, Seyed Javad Moghaddam, Seyed Javad
| Texas Medical Center
RAS mutations are among the most common oncogenic mutations in human cancers. Among RAS mutations, KRAS has the highest frequency and is present in almost 30% of non-small-cell lung cancer (NSCLC) patients. Lung cancer is the number one cause of mortality among cancers as a consequence of outrageous aggressiveness and late diagnosis. High mortality rates have been the reason behind numerous investigations and clinical trials to discover proper therapeutic agents targeting KRAS.
Open in Who Shared Issue with article?

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions

|
By Seyed Javad Moghaddam, Seyed Javad, Nastaran Karimi
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open in Who Shared Issue with article?
See all 3 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Nastaran

Contact Nastaran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified